{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:08:58Z","timestamp":1790096938938,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104792","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:22:13Z","timestamp":1788222133000},"page":"104792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rare disease benchmarks: Investment professionals\u2019 accuracy and beliefs"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-8554","authenticated-orcid":false,"given":"Jonathan","family":"Ilicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7819-1906","authenticated-orcid":false,"given":"Alexander J.","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104792_b0005","series-title":"Pharma R&D Annual Review 2025","author":"Citeline","year":"2025"},{"key":"10.1016\/j.drudis.2026.104792_b0010","article-title":"Evidence available and used by the Food and Drug Administration for the approval of orphan and nonorphan drugs","volume":"3","author":"Koong","year":"2025","journal-title":"Health Aff Sch"},{"key":"10.1016\/j.drudis.2026.104792_b0015","series-title":"Orphan Drug Report 2024","author":"Evaluate Ltd","year":"2024"},{"key":"10.1016\/j.drudis.2026.104792_b0020","series-title":"NEXT Report 2023","author":"Global Genes","year":"2023"},{"key":"10.1016\/j.drudis.2026.104792_b0025","article-title":"The IRDiRC Chrysalis Task Force: making rare disease research attractive to companies","volume":"4","author":"Beaverson","year":"2023","journal-title":"Ther Adv Rare Dis"},{"key":"10.1016\/j.drudis.2026.104792_b0030","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1126\/science.185.4157.1124","article-title":"Judgment under uncertainty: heuristics and biases","volume":"185","author":"Tversky","year":"1974","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104792_b0035","series-title":"Expert Political Judgment: How Good Is It? How Can We Know?","author":"Tetlock","year":"2005"},{"key":"10.1016\/j.drudis.2026.104792_b0040","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1037\/a0016755","article-title":"Conditions for intuitive expertise: a failure to disagree","volume":"64","author":"Kahneman","year":"2009","journal-title":"Am Psychol"},{"key":"10.1016\/j.drudis.2026.104792_b0045","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1287\/orsc.1100.0621","article-title":"Organizational learning: from experience to knowledge","volume":"22","author":"Argote","year":"2011","journal-title":"Organ Sci"},{"key":"10.1016\/j.drudis.2026.104792_b0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2836","article-title":"Acquiring orphans: will your orphan drug startup draw acquisition interest?","volume":"32","author":"Rooswinkel","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2026.104792_b0055","unstructured":"ZS Associates. Rare, but ready: why the future of pharma runs through rare disease; 2025. https:\/\/www.zs.com\/insights\/rare-disease-pharma-innovation (accessed 8 Jul 2026)."},{"key":"10.1016\/j.drudis.2026.104792_b0060","unstructured":"Ford J, Corvino B, Blair A, Elsner N, Wagh M. Drug launches reflect overall company performance. Deloitte Insights; 2023. https:\/\/www.deloitte.com\/us\/en\/insights\/industry\/health-care\/key-factors-for-successful-drug-launch.html (accessed 8 Jul 2026)."},{"key":"10.1016\/j.drudis.2026.104792_b0065","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jama.2023.3079","article-title":"Five-year sales for newly marketed prescription drugs with and without initial Orphan Drug Act designation","volume":"329","author":"Tu","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2026.104792_b0070","series-title":"Clinical Development Success Rates and Contributing Factors 2011\u20132020","author":"Thomas","year":"2021"},{"key":"10.1016\/j.drudis.2026.104792_b0075","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s43441-021-00364-y","article-title":"Valuation and returns of drug development companies: lessons for bioentrepreneurs and investors","volume":"56","author":"Michaeli","year":"2022","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.drudis.2026.104792_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164681","article-title":"Profitability and market value of orphan drug companies: a retrospective, propensity-matched case-control study","volume":"11","author":"Hughes","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104792_b0085","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-024-07316-0","article-title":"Refining the impact of genetic evidence on clinical success","volume":"629","author":"Minikel","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104792_b0090","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.drudis.2026.104792_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008489","article-title":"Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval","volume":"15","author":"King","year":"2019","journal-title":"PLoS Genet"},{"key":"10.1016\/j.drudis.2026.104792_b0100","unstructured":"Scala S, McCallister E, Baral R, Nedelcovych M, Werber Y. Biopharma BD: assessing China\u2019s innovation and industry\u2019s evolving appetite. Ahead of the Curve Series. TD Cowen (TD Securities); 6 Jan 2026. Subscription research report."},{"key":"10.1016\/j.drudis.2026.104792_b0105","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s13023-025-03933-8","article-title":"Spectrum and epidemiology of rare diseases in a Chinese natural population of 14.31 million residents, 2012\u20132023","volume":"20","author":"Li","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.drudis.2026.104792_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104568","article-title":"Non-oncology orphan drug development: productivity and probability of success","volume":"31","author":"Parker","year":"2026","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104792_b0115","doi-asserted-by":"crossref","DOI":"10.1007\/s11606-026-10403-9","article-title":"Systematic review: association between physicians\u2019 clinical experience and quality of care and patient outcomes","author":"Shimada","year":"2026","journal-title":"J Gen Intern Med"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:22:06Z","timestamp":1790094126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1359644626001972"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104792","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rare disease benchmarks: Investment professionals\u2019 accuracy and beliefs","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104792"}}